Digital-direct-RT-PCR: A sensitive and specific method for quantification of CTC in patients with cervical carcinoma

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Pfitzner, Claudia ^a   Schröder, Isabel ^a   Scheungraber, Cornelia ^a   Dogan, Askin ^a   Runnebaum, Ingo Bernhard ^a   Dürst, Matthias ^a   Häfner, Norman ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR MARKER; VIRUS DNA;

BLOOD; FEMALE; GENETICS; HELA CELL LINE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR EMBOLISM; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NEOPLASTIC CELLS, CIRCULATING; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 84893826489     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03970     Document Type: Article

References (33)

1. Diamandis, E. P. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102, 1462-7 (2010).
2. Negm, R. S., Verma, M. & Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol Med 8, 288-93 (2002). (Pubitemid 34568384)
3. Alix-Panabieres, C., Schwarzenbach, H. & Pantel, K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 63, 199-215 (2012).
4. Cristofanilli, M. et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23, 1420-30 (2005).
5. Paterlini-Brechot, P. & Benali, N. L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253, 180-204 (2007). (Pubitemid 47017533)
6. Pachmann, K. et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26, 1208-15 (2008).
7. Zieglschmid, V., Hollmann, C. & Bocher, O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 42, 155-96 (2005). (Pubitemid 41647727)
8. Bustin, S. A., Siddiqi, S., Ahmed, S., Hands, R. & Dorudi, S. Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients. Int J Cancer 108, 412-7 (2004). (Pubitemid 37549607)
9. Chelly, J., Concordet, J. P., Kaplan, J. C. & Kahn, A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci U S A 86, 2617-21 (1989). (Pubitemid 19112598)
10. Narod, S. A., Seth, A. & Nam, R. Fusion in the ETS gene family and prostate cancer. Br J Cancer 99, 847-51 (2008).
11. Salzman, J. et al. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol 9, e1001156 (2011).
12. Durst, M., Glitz, D., Schneider, A. & zur Hausen, H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189, 132-40 (1992).
13. Schwarz, E. et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314, 111-4 (1985). (Pubitemid 15142033)
14. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005). (Pubitemid 40372904)
15. Walboomers, J. M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-9 (1999). (Pubitemid 29406813)
16. Scheffner, M.,Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-36 (1990). (Pubitemid 120035062)
17. Gonzalez, S. L., Stremlau, M., He, X., Basile, J. R. &Munger, K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75, 7583-91 (2001). (Pubitemid 32738016)
18. von KnebelDoeberitz, M., Rittmuller, C., zur Hausen,H.&Durst, M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 51, 831-4 (1992).
19. Butz, K. et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938-45 (2003). (Pubitemid 37175872)
20. Hafner, N. et al. HPV16-E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse-transcription PCR. Int J Cancer 120, 1842-6 (2007). (Pubitemid 46418358)
21. Hafner, N. et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27, 1610-7 (2008). (Pubitemid 351347875)
22. Vogelstein, B. & Kinzler, K. W. Digital PCR. Proc Natl Acad Sci U S A 96, 9236-41 (1999). (Pubitemid 29374738)
23. Sykes, P. J. et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13, 444-9 (1992).
24. Sherman, L., Alloul, N., Golan, I., Durst, M. & Baram, A. Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized byHPV 16, and in cell lines established from cervical cancers. Int J Cancer 50, 356-64 (1992).
25. Hartung, R. et al. Application of an asymmetric helical tube reactor for fast identification of gene transcripts of pathogenic viruses by micro flow-through PCR. Biomed Microdevices 11, 685-92 (2009).
26. Bostick, P. J. et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16, 2632-40 (1998). (Pubitemid 28363026)
27. Jung, R. et al. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Br J Cancer 78, 1194-8 (1998). (Pubitemid 28479150)
28. Pao, C. C., Hor, J. J., Yang, F. P., Lin, C. Y. & Tseng, C. J. Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. J Clin Oncol 15, 1008-12 (1997). (Pubitemid 27106284)
29. Tseng, C. J. et al. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J Clin Oncol 17, 1391-6 (1999).
30. Scheungraber, C. et al. Detection of disseminated tumor cells in patients with cervical cancer. J Cancer Res Clin Oncol 128, 329-35 (2002). (Pubitemid 34569355)
31. Weismann, P. et al. The detection of circulating tumor cells expressing E6/E7 HRHPV oncogenes in peripheral blood in cervical cancer patients after radical hysterectomy. Neoplasma 56, 230-8 (2009).
32. Jacobs, M. V. et al. A general primer GP51/GP6(1)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35, 791-5 (1997). (Pubitemid 27083888)
33. Schmitz, M. et al. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 44, 302-7 (2009).